View Older Stories View More Recent Stories

Nov 13, 2020 08:00AM Horizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala
Nov 12, 2020 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Nov 2, 2020 02:00PM Horizon Therapeutics (HZNP) Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
Nov 2, 2020 02:00PM Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
Nov 2, 2020 07:00AM Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITD
Nov 2, 2020 06:58AM Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
Oct 30, 2020 09:15AM Chicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year
Oct 30, 2020 08:00AM New TEPEZZA® (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting
Oct 29, 2020 08:00AM Horizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout
Oct 26, 2020 08:00AM Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business
Oct 23, 2020 08:00AM Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
Oct 22, 2020 10:00AM New Data Offers Insights on Treatment with KRYSTEXXA® (pegloticase injection) Among Kidney Transplant Patients for the Management of Uncontrolled Gout
Oct 20, 2020 08:00AM Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the Chicago Innovation Award
Oct 16, 2020 08:30AM FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Medium Workplaces List for Fifth Consecutive Year
Oct 14, 2020 08:03AM Horizon Therapeutics (HZNP) Reports TEPEZZA (teprotumumab-trbw) Data from Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease
Oct 14, 2020 08:00AM TEPEZZA® (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)
Oct 8, 2020 08:15AM New Data Evaluating KRYSTEXXA® (pegloticase injection) With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020
Oct 8, 2020 08:00AM Horizon Therapeutics plc to Release Third-Quarter 2020 Financial Results and Host Webcast on Nov. 2, 2020
Oct 7, 2020 08:00AM Horizon Therapeutics plc Named One of San Francisco Bay Area’s Best and Brightest Companies to Work For
Oct 5, 2020 08:00AM Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the R&D 100 Award
Oct 1, 2020 04:00PM Horizon Therapeutics plc Named as an Angels in Adoption® Honoree by U.S. Congressional Coalition on Adoption for #RAREis Adoption Fund partnership with Gift of Adoption
Sep 16, 2020 08:09AM Horizon Therapeutics (HZNP) MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79% of Patients Achieved Complete Response Using KRYSTEXXA with Methotrexate
Sep 16, 2020 08:00AM MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Sep 2, 2020 09:00AM Horizon Therapeutics plc Named to the 2020 PEOPLE “50 Companies That Care” List
Sep 1, 2020 08:00AM Horizon Therapeutics plc to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Aug 10, 2020 09:00AM Horizon Therapeutics Named one of the Best Places to Work in Chicago by Crain’s Chicago Business
Aug 6, 2020 09:00AM Horizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune
Aug 5, 2020 07:00AM Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full‐Year 2020 Net Sales and Adjusted EB
Jul 31, 2020 07:12AM Horizon Therapeutics (HZNP) New Topline TEPEZZA Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with TED
Jul 31, 2020 07:00AM New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)
Jul 22, 2020 08:07AM Horizon Therapeutics (HZNP) Reports Target Patient Enrollment in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA (pegloticase injection) Co-Prescribed with Methotrexate
Jul 22, 2020 08:00AM Target Enrollment Reached in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) Co-Prescribed with Methotrexate as an Immunomodulator to Enhance Response Rates for Peopl
Jul 13, 2020 08:30AM Horizon Therapeutics plc to Release Second-Quarter 2020 Financial Results and Host Webcast on Aug. 5, 2020
Jul 9, 2020 08:39AM Horizon Therapeutics (HZNP) Announces CMS Issues Permanent J-Code for TEPEZZA Effective Oct. 1, 2020
Jul 9, 2020 08:30AM Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for TEPEZZA® (teprotumumab-trbw) Effective Oct. 1, 2020
Jul 1, 2020 09:00AM New Initiative Encourages the Graves’ Disease Community to FOCUS on Eye Health
Jun 3, 2020 08:05AM Horizon Therapeutics plc Announces Redemption of All $400 Million of Its Exchangeable Senior Notes
Jun 3, 2020 08:00AM Data Presented on KRYSTEXXA® (pegloticase injection) Co-Prescribed with an Immunomodulator Adds to Growing Body of Evidence for this Treatment Approach
May 21, 2020 09:15AM Horizon Therapeutics Named Number One Best Workplace in Chicago
May 21, 2020 08:00AM Data on Multiple Immunomodulation Approaches with KRYSTEXXA® (pegloticase injection) to be Presented at the Annual European Congress of Rheumatology (EULAR 2020)
May 19, 2020 08:00AM Horizon Therapeutics to Participate in Upcoming Investor Conferences
May 14, 2020 09:04AM Horizon Therapeutics (HZNP) Announces New Data on Pharmacokinetic Profile of TEPEZZA Reinforce Labeled Dosing Regimen, Indicating Positive, Consistent Response to Therapy
May 14, 2020 09:00AM New Data on the Pharmacokinetic Profile of TEPEZZA™ (teprotumumab-trbw) Reinforce the Labeled Dosing Regimen, Indicating a Positive, Consistent Response to Therapy
May 11, 2020 12:00PM U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of Life
May 6, 2020 07:00AM Horizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA™ Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-
Apr 27, 2020 08:10AM Horizon Therapeutics plc Announces Availability of PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets in the United States
Apr 15, 2020 08:00AM Horizon Therapeutics plc to Release First-Quarter 2020 Financial Results and Host Webcast on May 6, 2020
Apr 9, 2020 09:00AM Horizon Therapeutics plc Named One of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®
Apr 2, 2020 08:11AM Horizon Therapeutics (HZNP) Acquires Curzion Pharmaceuticals
Apr 2, 2020 08:00AM Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
View More Recent Stories View Older Stories